Answers are grounded in this paper and cite their sources.
The worldwide hearing loss disability for more than 1.5 billion disproportionately affects the lives and livelihoods of those in low- and middle-income countries (LMIC). Hearing aids are the predominant treatment; however, their impact is modest, and they are less available in LMIC where the need is greatest. Moreover, hearing loss is the #1 mid-life risk factor for dementia. Sensorineural hearing loss (SNHL), the most common form of hearing loss, is a metabolic stress disorder compounded by vasospasm, leading to mitochondrial DNA (mtDNA) dysfunction. The micronutrient formula ACEMg was developed to block SNHL and successfully tested on animal models. We report findings from a real-world evidence (RWE) study (N=190) conducted to assess whether ACEMg impacts SNHL in humans. Real-world data (RWD) from distortion product otoacoustic emissions (OAE) examinations were collected from patients previously diagnosed with SNHL. OAE examinations produce objective measures of the auditory function of outer hair cells (OHC) in the cochlea. Analyses of RWD from OAE examinations in the treatment group (N=93), who used ACEMg as softgel capsules, compared with OAE RWD from the untreated group (N=97) demonstrate ACEMg significantly preserved and improved auditory function. OAE scores over two years increased or remained unchanged for 75.3% of those in the treatment group. OAE scores decreased for 73.2% of those in the untreated group (X2, 2,190=54.08, p<.001). Findings justify analyses of additional RWD to further quantify ACEMg impact.
No takes yet. Share an insight, caveat, or question.
Seifer et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: